Skip to content

Massimiliano Aragona

3 papers in the library · 226 citations · publishing 2009-2026

Papers

Sort Most recent Most cited

Phenomenology of Hallucinations in Endogenous and Substance-Related Exogenous Psychoses.

Psychopathology 2026 Valerio Ricci, Massimiliano Aragona, Giuseppe Maina et al. 1 citation

Healthcare professionals encounter challenges in discerning endogenous and exogenous, drug-related, psychopathological phenomena. This study aimed to explore qualitative differences between hallucinations in schizophrenia and two forms of substance-related psychosis. These are substance-induced psychosis (SIP), which has an acute onset and is usually transient, and substance-related persistent...

DOI: 10.1159/000547087 (opens in new tab) Full text (opens in new tab) Phenomenology Exogenous psychosis Hallucinations Schizophrenia +1

The lived experience of psychosis: a bottom-up review co-written by experts by experience and academics.

World Psychiatry June 1, 2022 Paolo Fusar‐poli, Andrés Estradé, Giovanni Stanghellini et al. 225 citations

Psychosis is the most ineffable experience of mental disorder. We provide here the first co-written bottom-up review of the lived experience of psychosis, whereby experts by experience primarily selected the subjective themes, that were subsequently enriched by phenomenologically-informed perspectives. First-person accounts within and outside the medical field were screened and discussed in...

Psychopathological and cognitive effects of therapeutic cannabinoids in multiple sclerosis: a double-blind, placebo controlled, crossover study.

Clinical Neuropharmacology 2009 Massimiliano Aragona, Emanuela Onesti, Valentina Tomassini et al.

To study possible psychopathological symptoms and cognitive deficits, abuse induction, as well as general tolerability and effects on quality of life, fatigue and motor function in cannabis-naïve patients with multiple sclerosis (MS) treated with a free-dose cannabis plant extract (Sativex). In an 8-week, randomized, double-blind, placebo-controlled, parallel group crossover trial, 17...